VK2809 mit guten Phase 2 Studienergebnissen
https://seekingalpha.com/news/...d-study-shares-128-percent-premarket
Viking meldet Zahlen für 2018
http://ir.vikingtherapeutics.com/...lts-and-Provides-Corporate-Update
Viking Therapeutics to Present New Data from Phase 2 Study of VK2809 in Patients with Non-Alcoholic Fatty Liver Disease (NAFLD) and Elevated LDL-Cholesterol at The International Liver Congress? 2019
https://www.ariva.de/news/...sent-new-data-from-phase-2-study-7508084